Related Experiment Videos
New drugs in clinical development in the United States
1University of Texas Health Science Center, San Antonio.
Abstract:
Over the past few years, a number of new antineoplastic agents have reached the clinical arena. These agents have demonstrated activity in a wide variety of preclinical tumor models and many have been found to have novel mechanisms of action. Some of these new agents are now in Phase I and Phase II trials demonstrating antitumor activity and unique toxicity profiles. In this article, the authors review some of the new agents in clinical development in the United States.
Insights
New antineoplastic agents show promise in preclinical models and early clinical trials. This review highlights novel cancer therapies in US development, focusing on mechanisms and toxicity.
Area of Science:
- Oncology
- Pharmacology
Background:
- Recent advancements in cancer treatment have introduced novel antineoplastic agents.
- Many of these agents exhibit unique mechanisms of action and have shown efficacy in preclinical tumor models.
Purpose of the Study:
- To review emerging antineoplastic agents currently in clinical development within the United States.
- To highlight agents with novel mechanisms of action and promising preclinical data.
Main Methods:
- Review of new antineoplastic agents in clinical development.
- Analysis of preclinical data, including tumor model activity.
- Examination of early-phase clinical trial (Phase I and II) results.
Main Results:
- Several new antineoplastic agents have demonstrated significant antitumor activity.
- These agents often possess novel mechanisms of action.
- Unique toxicity profiles are being observed in early clinical trials.
Conclusions:
- New antineoplastic agents are progressing through clinical trials in the US.
- These agents represent a potential advancement in cancer therapy.
- Further investigation is warranted to understand their full therapeutic potential and safety profiles.